HIF1A and nasopharyngeal carcinoma: Our approach to use combination therapy with Axitinib and PX-478 provides a means to circumvent the development of resistance to conventional antiangiogenesis therapy, and the finding of the role of HIF-1α in EBV-induced VM opens a new avenue to further explore the clinical use of HIF-1α inhibitors in NPC and EBVaGC.